Disease relevance of Ultravist

• A control group received iopromide 370 alone while the treatment group was injected with a iopromide-protaxel formulation at a dose of 74 micromol/l, which is far below protaxel levels inducing systemic toxicity [1].
• Each examination included the entire kidneys and was performed after injection of 120 mL iopromide and 300 mg of iodine per milliliter given per 75 kg of body weight [2].
• RESULTS: Single and double doses of iopromide did not affect infarction volume or neurologic performance [3].
• We studied the effect of an ionic high osmolar contrast medium (Ioxitalamate), an ionic low osmolar contrast medium (Ioxaglate) and various nonionic low osmolar contrast media (Iopamidol, Iopromide and Iohexol) on thrombus growth in a rabbit jugular vein thrombosis model [4].
• CONCLUSION: Bolus injection of the nonionic iopromide does not statistically significantly affect infarction volume or cerebral ischemia symptoms [3].

Psychiatry related information on Ultravist

• Group 2 (n = 21) ingested 10-mL aliquots of nonionic iodinated contrast material (iopromide) with a concentration of 300 mg per milliliter with meals and snacks for 2 days before imaging, without diet modification or a cathartic [5].

High impact information on Ultravist

• A further comparison between GFR determined with iohexol and iopromide, a new low-osmolarity, low-viscosity contrast medium, was also performed in a subgroup of patients.(ABSTRACT TRUNCATED AT 250 WORDS)[6]
• New compounds, such as iodinated polymers for x-ray perfusion imaging and iopromide- or metrizamide-containing liposomes allowing liver enhancement are discussed [7].
• However there was a more dramatic decrease in phosphorylation of the phosphorylated form of mammalian target of rapamycin (mTOR) and of the extracellular-signal regulated kinases (ERK) 1/2 caused by sodium diatrizoate than by iopromide [8].
• All the patients underwent cystography in the supine position by retrograde filling of the bladder with a 50% dilute solution of 300 mgI/ml iopromide in serial increments of 50 ml up to a maximum of 350 ml [9].
• CONCLUSION: These findings indicate that the determination of plasma clearance of iohexol/iopromide is a simple, rapid, and accurate method that can indeed be used for estimating GFR in ICU patients with normal renal function or even different degrees of renal insufficiency [10].

Chemical compound and disease context of Ultravist

• The experiments were repeated in rabbits using CT imaging and iopromide or iotrolan plus urea (52 mg/mL) or iloprost (20 ng/mL) and iodine doses of 50 mg/kg body weight [11].
• Our aim was to determine whether large central venous doses of ionic diatrizoate, nonionic iopromide, or nonionic iotrolane produce pulmonary edema or pulmonary congestion in dogs [12].
• Administration of iopromide for pulmonary angiography in patients with pulmonary hypertension resulted in no appreciable hemodynamic alterations associated with the observed changes in atrial natriuretic peptide, antidiuretic hormone, and renin [13].
• The administration of the nonionic dimeric contrast medium iodixanol, or of the nonionic monomer iopromide, entailed a low nephrotoxic potential in patients with mild to moderate renal insufficiency undergoing excretory urography [14].
• METHODS: We prospectively studied 50 patients with chronic renal insufficiency (serum creatinine concentration greater than 1.58 mg/dl) who underwent spiral CTA with iopromide, a nonionic, low-osmolar contrast agent [15].

Biological context of Ultravist

• Pharmacokinetics of iopromide liposomes in rabbits [16].
• RESULTS: Iopromide, Ioxaglate, and Ioxatalamate induced apoptosis in all cell cultures at final concentrations ranged from 0.1% to 10.0% [17].
• The kinetics of iopromide 240 after intrathecal administration are characterized by a prolonged half-life [18].
• RESULTS: Cell growth was more severely inhibited by ioxithalamate than iopromide (p < 0.05) and strongly dependent on the osmolality of contrast agent [19].
• In rabbits, at a dose of 300 mg total iodine per kilogram, the iopromide-carrying liposomes displayed prolonged blood circulation, with mean CT density differences > 60 Hounsfield units (aorta) for up to 10 minutes [20].

Anatomical context of Ultravist

• The interaction of iopromide with proteins and membranes was found to be considerably low due to its hydrophilicity [21].
• The nonionic contrast media iotrolan and iopromide caused mild to moderate changes in endothelial cells [22].
• At the origin of coronary arteries, the mean attenuation after iomeprol 400 (340+/-53 HU) was greater (P<0.05) than that after iopromide 370 (313+/- 42 HU) [23].
• RESULTS: The iopromide-carrying liposomes caused only minor morphological changes in dog erythrocytes [20].
• Iopromide was administered as a total of 100 mL via a 7F catheter inserted from the right femoral vein [13].

Associations of Ultravist with other chemical compounds

• 4 In isolated perfused arteries the depressor responses to iodixanol (320 mg ml-1) and iopromide (300 mg ml-1) administered as close arterial bolus attained a plateau with maximal dilatations of approximately 25% and approximately 60%, respectively [24].
• Two prospective, double-blind, randomized comparative clinical trials compared the safety profile, tolerance, and diagnostic quality of iopromide with two control drugs, iopamidol and iohexol [25].
• Vertebral artery injections of methylglucamine diatrizoate 60%, iopromide, and iotrolan in the rabbit [26].
• CONCLUSIONS: Under the experimental conditions iopromide, ioxaglate, and iosimenol had no or very similar direct or otherwise mediated effect on cell proliferation and restenosis [27].
• Both ionic (sodium meglumine diatrizoate, methylglucamine diatrizoate, and sodium meglumine ioxaglate and nonionic CM (iosimide, iopromide, iohexol and iotrolan) were able to induce MN in lymphocytes [28].

Gene context of Ultravist

• CONCLUSION: In the normal rat, activation of ET-A receptors is partly involved in the depression of outer medullary pO2 caused by injection of iopromide [29].
• A significant increase of PAI-1 levels was seen in the Ultravist group but not in the Hypaque group [30].
• Among the kidney-specific enzymes, the excretion of GGT in urine increased after injection of iopromide and iopamidol [31].
• CONCLUSIONS: This study demonstrates the lack of release of ET-1 by iopromide [32].
• Iopromide caused no appreciable hemodynamic alterations associated with the changes in atrial natriuretic peptide and antidiuretic hormone and no evidence of allergy-mediated reactions in all volunteers [33].

Analytical, diagnostic and therapeutic context of Ultravist

• MATERIALS AND METHODS: One hundred two patients (64 men, 38 women) with neoplastic (n = 85) and nonneoplastic focal lesions (n = 17) were prospectively assigned to biphasic injection group A or B and received 180 mL of iopromide containing 370 or 300 mg of iodine per milliliter, respectively, during spiral CT [34].
• Safety and efficacy of iopromide in cerebral arteriography [35].
• Efficacy and safety of iopromide for excretory urography [36].
• Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting [37].
• METHODS: Eleven patients with an indication for lumbar myelography received 10 mL iopromide 240 in an open, prospective, single-center study [18].

References